

The famous Wusi Square monument, symbol of Qingdao City, China. Please read the important clinical trial by Wan *et al* looking at the effects of dietary fat on gut microbiota and faecal metabolites.

An international journal of gastroenterology and hepatology

Impact Factor: 17.943

Editor

Emad El-Omar (Australia)

Deputy Editor (Hepatology)

Alexander Gerbes (Germany)

Deputy Editor (Luminal

Gastroenterology)

William Grady (USA)

Deputy Editor (Endoscopy)

Thomas Rosch (Germany)

Associate Editors

Guy Boeckstaens (Belgium)

Patrice Cani (Belgium)

Jean-Francois Dufour (Switzerland)

Thomas Gress (Germany)

Christian Jobin (USA)

Arthur Kaser (UK)

Ernst Kuipers (The Netherlands)

Siew C Ng (Hong Kong)

Robert Thimme (Germany)

Herbert Tilg (Austria)

Fabien Zoulim (France)

Editorial Office

Gut

BMJ Journals

BMA House, Tavistock Square

London, WC1H 9JR, UK

E: [info.gut@bmj.com](mailto:info.gut@bmj.com)

ISSN: 0017-5749 (print)

ISSN: 1468-3288 (online)

**Disclaimer:** Gut is owned and published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association and the British Society of Gastroenterology. The owners grant editorial freedom to the Editor of Gut. Gut follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Gut is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the British Society of Gastroenterology or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of Gut or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright** © 2019 BMJ Publishing Group Ltd and British Society of Gastroenterology. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior permission

Gut is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Gut (ISSN: 0017-5749) is published monthly by BMJ Publishing Group and is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to Gut, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

## Debate

**1343** Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons!

*A M Drewes, M A Kempeneers, D K Andersen, L Arendt-Nielsen, M G Besselink, M A Boermeester, S Bouwense, M Bruno, M Freeman, T M Gress, J E van Hoofi, B Morlion, S S Olesen, H van Santvoort, V Singh, J Windsor*

## Commentaries

**1352** Is colonic propionate delivery a novel solution to improve metabolism and inflammation in overweight or obese subjects?

*P D Cani*

**1353** Microbiota as a cornerstone in the development of primary sclerosing cholangitis: paving the path for translational diagnostic and therapeutic approaches

*C Mooser, S C Ganai-Vonarburg*

## Guidelines

**1356** British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

*M H Chapman, D Thorburn, G M Hirschfield, G G J Webster, S M Rushbrook, G Alexander, J Collier, J K Dyson, D E J Jones, I Patanwala, C Thain, M Walmsley, S P Pereira*

## Oesophagus

**1379** Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study

*S S Sami, A Ravindran, A Kahn, D Snyder, J Santiago, J Ortiz-Fernandez-Sordo, W K Tan, R A Dierkhising, J E Crook, M G Heckman, M L Johnson, R Lansing, K Raganath, M di Pietro, H Wolfsen, F Ramirez, D Fleischer, K K Wang, C L Leggett, D A Katzka, P G Iyer*

## Inflammatory bowel disease

**1386** A blood-based prognostic biomarker in IBD

*D Biasci, J C Lee, N M Noor, D R Pombal, M Hou, N Lewis, T Ahmad, A Hart, M Parkes, E F McKinney, P A Lyons, K G C Smith*

## Coeliac disease

**1396** NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study  
*M Cheminant, J Bruneau, G Malamut, D Sibon, N Guegan, T van Gils, S Cording, A Trinquand, V Verkarre, L Lhermitte, N Brousse, A-S Jannot, S Khater, L Frenzel, R Delarue, F Suarez, A Marçais, C JJ Mulder, E Macintyre, V Asnafi, L Pouyet, C Bonnafous, F Lhospice, T J Molina, B Meresse, C Cellier, N Cerf-Bensussan, O Hermine, for the CELAC network<sup>o</sup>*

## Neurogastroenterology

**1406** Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons


*N Stakenborg, E Labeuw, P J Gomez-Pinilla, S De Schepper, R Aerts, G Goverse, G Farro, I Appeltans, E Meroni, M Stakenborg, M F Viola, E Gonzalez-Dominguez, G Bosmans, Y A Alpizar, A Wolhuis, A D'Hoore, K Van Beek, S Verheijden, M Verhaegen, R Derua, E Waelkens, M Moretti, C Gotti, P Augustijns, K Talavera, P Vanden Berghe, G Matteoli, G E Boeckstaens*


## Gut microbiota

**1417** Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial

*Y Wan, F Wang, J Yuan, J Li, D Jiang, J Zhang, H Li, R Wang, J Tang, T Huang, J Zheng, A J Sinclair, J Mann, D Li*

MORE CONTENTS ►

 This article has been chosen by the Editor to be of special interest or importance and is freely available online.

 This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

COPE  
Member since 2008  
JMB0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics  
[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

 equator network

 recycle  
When you have finished with this magazine please recycle it.

- 1430** Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial



OPEN ACCESS

*E S Chambers, C S Byrne, D J Morrison, K G Murphy, T Preston, C Tedford, I Garcia-Perez, S Fountana, J I Serrano-Contreras, E Holmes, C J Reynolds, J F Roberts, R J Boyton, D M Altmann, J A K McDonald, J R Marchesi, A N Akbar, N E Riddell, G A Wallis, G S Frost*

- 1439** Identification of TMAO-producer phenotype and host–diet–gut dysbiosis by carnitine challenge test in human and germ-free mice



OPEN ACCESS

*W-K Wu, C-C Chen, P-Y Liu, S Panyod, B-Y Liao, P-C Chen, H-L Kao, H-C Kuo, C-H Kuo, T H T Chiu, R-A Chen, H-L Chuang, Y-T Huang, H-B Zou, C-C Hsu, T-Y Chang, C-L Lin, C-T Ho, H-T Yu, L-Y Sheen, M-S Wu*

## Colon

- 1450** Participation and yield of a population-based colorectal cancer screening programme in China
- H Chen, N Li, J Ren, X Feng, Z Lyu, L Wei, X Li, L Guo, Z Zheng, S Zou, Y Zhang, J Li, K Zhang, W Chen, M Dai, J He, the group of Cancer Screening Program in Urban China (CanSPUC)*

## GI cancer

- 1458** Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink
- Z Liu, R Alsagoff, K A McGlynn, L A Anderson, H-T Tsai, B Zhu, Y Zhu, S M Mbulaiteye, S M Gadalla, J Koshiol*

## Pancreas

- 1465** DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
- J Luna, J Boni, M Cuatrecasas, X Bofill-De Ros, E Núñez-Manchón, M Gironella, E C Vaquero, M L Arbones, S de la Luna, C Fillat*

## Hepatology

- 1477** Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis
- L Liao, K M Schneider, E J C Galvez, M Frissen, H-U Marschall, H Su, M Hattig, A Wahlström, J Haybaeck, P Puchas, A Mohs, J Peng, I Bergheim, A Nier, J Hennings, J Reißing, H W Zimmermann, T Longerich, T Strowig, C Liedtke, F J Cubero, C Trautwein*

- 1493** Fine needle aspirates comprehensively sample intrahepatic immunity



OPEN ACCESS

*U S Gill, L J Pallett, N Thomas, A R Burton, A A Patel, S Yona, P T F Kennedy, M K Maini*

- 1504** Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice
- T Hendriks, Y Duan, Y Wang, J-H Oh, L M Alexander, W Huang, P Stärkel, S B Ho, B Gao, O Fiehn, P Emond, H Sokol, J-P van Pijkeren, B Schnabl*

## Recent advances in basic science

- 1516** Leaky gut: mechanisms, measurement and clinical implications in humans
- M Camilleri*

## JournalScan

- 1527** GI highlights from the literature
- M H McLean*

## PostScript

- 1529** Letters

## Editor's quiz: GI snapshot

- 1385** Chronic GI bleeding in a middle-aged woman
- H Kitamoto, M Fukushima, T Inokuma*



OPEN ACCESS